Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IA/IB Trial of Modulation of the Biological Response to Interleukin-2 (IL-2) With Bryostatin 1 (BRYO; NSC 339555)

NCT00006022 is registered in ClinicalTrials.gov with Virginia Commonwealth University as lead sponsor.

NCT NCT00006022
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00006022 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IA/IB Trial of Modulation of the Biological Response to Interleukin-2 (IL-2) With Bryostatin 1 (BRYO; NSC 339555)
Lead sponsor
Virginia Commonwealth University
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2000
Completion date
January 31, 2004
Enrollment
17 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

kidney cancer, melanoma (skin)